Moderna, Bayer Lead $275M Series B Funding for Metagenomi: Unlocking the Power of Microbes for a Healthier World

Metagenomi is starting the new year off with a bang, having just secured an additional $100 million in a Series B extension financing round announced Thursday. This brings the total Series B to a whopping $275 million, with the round being led by Leaps by Bayer, Moderna and several other investors. It’s clear that Metagenomi’s efforts in 2022 have been recognized by the big pharma giants, and they’re looking forward to what the biotech can do in the coming year!

At November’s end, Metagenomi inked a deal with Ionis to deliver investigational medicines for up to four targets, and CEO and founder Brian Thomas celebrated the news with Thursday’s announcement. Thomas highlighted Metagenomi’s recent gene editing portfolio expansion and inaugural nonhuman primate studies, noting that the extra funding would enable them to “gain visibility on initial clinical milestones” and expand their in vivo pipeline. The news was a long time coming, as the company had presented at multiple conferences throughout the year.

Metagenomi has long been a proponent of partnerships, and that strategy has paid off with their recent deal with Ionis, which is projected to bring in a whopping $3 billion in biobucks. But that’s not all! This year, the company has also been chosen by Moderna to spearhead its gene editing endeavors, further cementing its standing as a leader in the field.

Metagenomi, a biotech company, recently made waves in the industry with their first partnership – a collaboration with Moderna Genomics. The partnership was anything but unexpected, as Eric Huang, the general manager and chief scientific officer of Moderna Genomics, had been a member of Metagenomi’s science advisory board for a while. This exciting development is a big step for Metagenomi, and could be the beginning of great things to come.

Thursday’s announcement saw Thomas praise his team for their hard work in forging new strategic business development alliances, hinting at the potential of further partnership announcements to come.

Leave a Comment